Allovir IncNASDAQ:ALVRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7350
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7350/ 95
- Ask / Lots0.7610/ 1
- Open / Previous Close0.7350 / 0.7350
- Day Range
- 52 Week Range
- Volume216,111
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVR |
|---|---|---|
| 09:36 ET | 100 | 0.749 |
| 09:38 ET | 100 | 0.749 |
| 09:39 ET | 100 | 0.749 |
| 09:43 ET | 459 | 0.7494 |
| 09:45 ET | 3743 | 0.749 |
| 09:48 ET | 16895 | 0.745 |
| 09:50 ET | 5194 | 0.7342 |
| 09:52 ET | 2700 | 0.735 |
| 09:54 ET | 2085 | 0.735 |
| 09:56 ET | 200 | 0.735 |
| 09:57 ET | 400 | 0.7381 |
| 09:59 ET | 500 | 0.7381 |
| 10:01 ET | 400 | 0.7381 |
| 10:03 ET | 300 | 0.73655 |
| 10:08 ET | 678 | 0.735 |
| 10:10 ET | 300 | 0.7381 |
| 10:15 ET | 100 | 0.7381 |
| 10:17 ET | 353 | 0.7366 |
| 10:19 ET | 1300 | 0.7381 |
| 10:21 ET | 200 | 0.7381 |
| 10:24 ET | 700 | 0.7382 |
| 10:26 ET | 300 | 0.7369 |
| 10:28 ET | 1000 | 0.7369 |
| 10:32 ET | 782 | 0.7382 |
| 10:33 ET | 100 | 0.7382 |
| 10:37 ET | 2073 | 0.7367 |
| 10:39 ET | 500 | 0.7383 |
| 10:42 ET | 121 | 0.7367 |
| 10:46 ET | 583 | 0.7352 |
| 10:48 ET | 100 | 0.7351 |
| 10:50 ET | 100 | 0.73665 |
| 10:51 ET | 1992 | 0.735 |
| 10:53 ET | 15973 | 0.735 |
| 10:55 ET | 1712 | 0.7351 |
| 10:57 ET | 5288 | 0.735 |
| 11:00 ET | 18772 | 0.735 |
| 11:02 ET | 294 | 0.73505 |
| 11:04 ET | 374 | 0.735 |
| 11:06 ET | 304 | 0.735 |
| 11:09 ET | 1307 | 0.735 |
| 11:11 ET | 500 | 0.7351 |
| 11:13 ET | 297 | 0.7351 |
| 11:15 ET | 447 | 0.735 |
| 11:18 ET | 200 | 0.735 |
| 11:20 ET | 290 | 0.7357 |
| 11:22 ET | 571 | 0.7357 |
| 11:24 ET | 834 | 0.7354 |
| 11:26 ET | 300 | 0.7357 |
| 11:27 ET | 1284 | 0.7357 |
| 11:29 ET | 1797 | 0.7367 |
| 11:33 ET | 200 | 0.7382 |
| 11:36 ET | 328 | 0.7367 |
| 11:38 ET | 771 | 0.7367 |
| 11:40 ET | 124 | 0.7367 |
| 11:42 ET | 100 | 0.7382 |
| 11:44 ET | 357 | 0.7382 |
| 11:47 ET | 1598 | 0.7343 |
| 11:49 ET | 366 | 0.7383 |
| 11:54 ET | 818 | 0.7382 |
| 11:58 ET | 5031 | 0.7303 |
| 12:00 ET | 3313 | 0.7302 |
| 12:02 ET | 100 | 0.7303 |
| 12:03 ET | 400 | 0.73175 |
| 12:05 ET | 6155 | 0.733 |
| 12:12 ET | 381 | 0.7331 |
| 12:16 ET | 300 | 0.7304 |
| 12:18 ET | 701 | 0.7303 |
| 12:20 ET | 200 | 0.7312 |
| 12:21 ET | 4356 | 0.7317 |
| 12:23 ET | 1281 | 0.7318 |
| 12:25 ET | 12360 | 0.7331 |
| 12:27 ET | 13062 | 0.7381 |
| 12:30 ET | 269 | 0.7381 |
| 12:32 ET | 9577 | 0.7357 |
| 12:34 ET | 678 | 0.7357 |
| 12:36 ET | 612 | 0.7358 |
| 12:38 ET | 216 | 0.7358 |
| 12:39 ET | 992 | 0.7358 |
| 12:41 ET | 789 | 0.735 |
| 12:43 ET | 1977 | 0.7372 |
| 12:45 ET | 769 | 0.7372 |
| 12:48 ET | 500 | 0.7371 |
| 12:50 ET | 1111 | 0.7381 |
| 12:52 ET | 492 | 0.7381 |
| 12:54 ET | 5300 | 0.7398 |
| 12:56 ET | 6481 | 0.7477 |
| 12:57 ET | 1383 | 0.7415 |
| 12:59 ET | 5828 | 0.735 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allovir Inc | 84.5M | -0.4x | --- |
Benitec Biopharma Inc | 81.5M | -0.9x | --- |
PMV Pharmaceuticals Inc | 80.8M | -1.2x | --- |
Tiziana Life Sciences Ltd | 88.6M | -5.5x | --- |
Relmada Therapeutics Inc | 90.2M | -1.0x | --- |
Adicet Bio Inc | 90.4M | -0.4x | --- |
Company Information
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Contact Information
- Headquarters
- 1100 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 617-433-2605
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- David Hallal
- President, Chief Financial Officer, Director
- Vikas Sinha
- Chief Executive Officer, Director
- Diana Brainard
- Co-Founder, Chief Scientific Officer
- Ann Leen
- Chief Accounting Officer
- Brett Hagen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $84.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 115.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-1.65 |
Book Value | $1.28 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
